How Reliable are Commercially Available Glypican4 ELISA Kits?

Abstract

Objective Glypican4 is an interesting new adipokine, which seems to play an important role in developmental processes and is potentially associated with metabolic changes in obesity and type 2 diabetes mellitus. Currently, only a few studies examined glypican4 in human blood, mainly in adults.

Design, Patients and Measurements The aim of our study was to investigate glypican4 serum levels in lean, overweight, and obese children and adolescents, to unravel a possible association between glypican4 serum levels and parameters of obesity and insulin resistance. In order to determine a suitable method for investigating glypican4 serum levels, we validated two commercially available human glypican4 ELISA kits, using serum and plasma samples of an obese, insulin-resistant patient, and a healthy control subject, a human recombinant glypican4 protein fragment and glypican4-overexpressing cell lysate.

Results Using ELISA kit #1 we were not able to detect values above background level, apart from standard curve values. ELISA kit #2 initially seemed suitable to measure glypican4, but further validation experiments showed non-linearity of serial dilutions, no recognition of a human recombinant glypican4 protein fragment and non-linearity in the recovery of glypican4-overexpressing cell lysate. In addition, there was a considerable decrease (approx. 68%) of measured values between two experiments, performed at different time points with aliquots of the same serum sample. Contrary to that, further experiments found sample stability not to be compromised.

Conclusions Extensive evaluation of the performance of two commercially available ELISA kits led to the conclusion that none of them is applicable for the measurement of glypican4 in human blood samples.

Key words

adipocytokines - obesity - humans - insulin resistance - obesity - enzyme-linked immunosorbent assay - diabetes -  autoimmunity

Publication History

Received: 23 March 2020
Received: 19 August 2020

Accepted: 04 September 2020

Article published online:
16 October 2020

• References

• 1 WHO. Global report on diabetes. Geneva: WHO Press World Health Organization; 2016
• 2 Guilherme A, Virbasius JV, Puri V. et al. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-377 DOI: 10.1038/nrm2391.
• 3 Sommerweiss D, Gorski T, Richter S. et al. Oleate rescues INS-1E β-cells from palmitate-induced apoptosis by preventing activation of the unfolded protein response. Biochem Biophys Res Commun 2013; 441: 770-776 DOI: 10.1016/j.bbrc.2013.10.130.
• 4 Ussar S, Bezy O, Blüher M. et al. Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine. Diabetes 2012; 61: 2289-2298 DOI: 10.2337/db11-1395.
• 5 Sakane H, Yamamoto H, Matsumoto S. et al. Localization of glypican-4 in different membrane microdomains is involved in the regulation of Wnt signaling. J Cell Sci 2012; 125 (Pt 2) 449-460. DOI: 10.1242/jcs.091876.
• 6 Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis 2008; 4: 68-75. doi:10.4161/org.4.2.5851
• 7 Flehmig G, Scholz M, Klöting N. et al. Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation. PLoS One 2014; 9: e99785. DOI: 10.1371/journal.pone.0099785.
• 8 Zhu HJ, Pan H, Cui Y. et al. The changes of serum glypican4 in obese patients with different glucose metabolism status. J Clin Endocrinol Metab 2014; 99: E2697-E2701. DOI: 10.1210/jc.2014-2018.
• 9 Cao J, Ma J, Sun L. et al. Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells. J Cell Biochem 2018; DOI: 10.1002/jcb.27266.
• 10 Li K, Xu X, Hu W. et al. Glypican-4 is increased in human subjects with impaired glucose tolerance and decreased in patients with newly diagnosed type 2 diabetes. Acta Diabetol 2014; 51: 981-990 DOI: 10.1007/s00592-014-0652-5.
• 11 Yoo HJ, Hwang SY, Cho GJ. et al. Association of glypican-4 with body fat distribution, insulin resistance, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2013; 98: 2897-2901. DOI: 10.1210/jc.2012-4297.
• 12 Leelalertlauw C, Korwutthikulrangsri M, Mahachoklertwattana P. et al. Serum glypican 4 level in obese children and its relation to degree of obesity. Clin Endocrinol (Oxf) 2017; 87: 689-695 DOI: 10.1111/cen.13435.
• 13 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Bioanalytical Method Validation: Guidance for Industry. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Updated May 24, 2018. Accessed February 12, 2020
• 14 Körner A, Garten A, Blüher M. et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007; 92: 4783-4791. DOI: 10.1210/jc.2007-1304.
• 15 Fisher J, Linder A, Bentzer P.. Elevated plasma glypicans are associated with organ failure in patients with infection. Intensive Care Med Exp 2019; 7: 2. doi:10.1186/s40635-018-0216-z
• 16 Lee SA, Koh G, Cho SJ. et al. Correlation of Glypican-4 Level with Basal Active Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes Mellitus. Endocrinol Metab (Seoul) 2016; 31: 439-445. DOI: 10.3803/EnM.2016.31.3.439.